TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05102253

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dense cranial electroacupuncture stimulation (DCEAS)
Description: DCEAS will be conducted for 2 sessions per week for 12 consecutive weeks. Electrical stimulation will be conducted on six pairs of forehead acupoints located on the frontal, parietal, and temporal scalp areas. The acupoints includes: Bai-Hui (GV20), Yin-Tang (EX-HN3), left and right Si-Shen-Cong (EX-HN1), Tou-Lin-Qi (GB15), Shuai-Gu (GB8), Tai-Yang (EX-HN5) and Tou-Wei (ST8).~Disposable acupuncture needles will be inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation will be carried out for all acupoints to evoke needling sensation, followed by electrical stimulation. The stimulation intensity will be adjusted to a level at which patients felt most comfortable. Each session of treatment will last 30 min.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS)
Description: TEAS will be done for 3 times per week for 12 consecutive weeks by participants at home. A training workshop will be conducted to instruct participants how to use TEAS stimulator. Briefly, TEAS will be delivered on the bilateral Nei-Guan (PC6), which is located on the anterior forearm, between the tendons of the palmaris longus and ﬂexor carpi radialis, at the junction of the distal sixth and proximal ﬁve sixths of the line connecting the middle points of the wrist and elbow crease.~Constant current electrical impulses will be produced from a TEAS apparatus. Two electrode pads will be adhered onto the acupoint skin. The pulse amplitude will be adjusted to a level at which the perception of 'strong but comfortable' is achieved. Each session of treatment will last 30 min.

Intervention type: OTHER
Group type: OTHER
Intervention: Wait-list control: Routine care
Description: The routine care may include medications, advocacy intervention, and CBT. Post-trial treatment of TEAS+DCEAS will be offered to serve as a compensation for their participation.
Study: NCT05124171

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BNT162b2
Description: ARM 1 receiving Pfizer-BioNTech vaccine~* Group 1.A: 18-64 years old~* Group 1.B: 65 years and older

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoV2 preS dTM adjuvanted vaccine (D614), Sanofi/GSK
Description: ARM 2 receiving SP/GSK subunit D614 vaccine~* Group 2.A: 18-64 years old~* Group 2.B: 65 years and older

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK
Description: ARM 3 receiving SP/GSK subunit B.1.351 vaccine~* Group 3.A: 18-64 years old~* Group 3.B: 65 years and older
Study: NCT05722223

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Trimodal prehabilitation
Description: Pancreatic cancer patients (not stage 4) will undergo trimodal prehabilitation: nutrition, psychological, and exercise support.
Study: NCT05477797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib DX/Lenalidomide DX
Description: After assessment of risk stratification，patients will be assigned to Id or Rd group randomly for maintenance therapy. Then they will be reviewed the efficacy monthly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ixazomib DX/Lenalidomide DX
Description: After assessment of risk stratification，patients will be assigned to Id or Rd group randomly for maintenance therapy. Then they will be reviewed the efficacy monthly.
Study: NCT05908201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: early time restricted eating
Description: The intervention group will eat in a prescribed daily feeding window (9am-5pm) and follow their normal exercise and resistance training routines. We will allow up till +/-1 hour for the eating window start and end times while aiming for an 8 hour eating window.
Study: NCT03763136

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: hPSC-CM Therapy
Description: Injection of allogenic human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) during coronary artery bypass grafting surgery. 200 million hPSC-CMs in 2.5-5 mL medium suspension will be injected into the myocardium.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hPSC-CM Therapy
Description: Injection of allogenic human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) during coronary artery bypass grafting surgery. 200 million hPSC-CMs in 2.5-5 mL medium suspension will be injected into the myocardium.
Study: NCT06502847

Intervention type: OTHER
Intervention: Exosome profile study
Description: Neonatal serum and maternal exosome profiles will be studied in all groups.

Intervention type: OTHER
Intervention: Exosome profile study
Description: Neonatal serum and maternal exosome profiles will be studied in all groups.

Intervention type: OTHER
Intervention: Exosome profile study
Description: Neonatal serum and maternal exosome profiles will be studied in all groups.
Study: NCT05301309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: breastfeeding consultation
Description: Integrative early breastfeeding support and intervention programs: breastfeeding for prematurity brochure, group education class, weekly interview, one-by-one breastfeeding consultation and online peer group support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: breastfeeding consultation
Description: Integrative early breastfeeding support and intervention programs: breastfeeding for prematurity brochure, group education class, weekly interview, one-by-one breastfeeding consultation and online peer group support.
Study: NCT05126849

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allogenic transplantation
Description: 1. Conditioning regimen Fludarabine (30mg/m2/day i.v: day -6 to day -2), pre-transplant cyclophosphamide (14.5 mg/kg/day i.v: day -6 and day -5), and Total Body Irradiation (2 Gray on day-1)~2. Stem cell source Bone Marrow~3. GVHD Prophylaxis Rabbit ATG dosed at 0.5 mg/kg on day -9 and 2 mg/kg on days -8 and -7, Cyclophosphamide 50 mg/Kg/day at D+3 and D+4, Tacrolimus (residual 8-12 microg/L) and mycophenolate (MMF) from D+5. In absence of GvHD, MMF will be stopped at D35 and tacrolimus at day 365.~4. Prevention of EBV reactivation Rituximab 150mg/m2 intravenously at Day+5 post HSCT, Each infusion of Rituximab will be preceded by administration of anti-pyretic and an antihistaminic, e.g. paracetamol and diphenhydramine.
Study: NCT06405477

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: L-arginine
Description: Capsules of 3 grams of L-arginine per Dose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: Capsules of 3 grams of L-arginine per Dose

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules of 3 grams of maize Starch per Dose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules of 3 grams of maize Starch per Dose
Study: NCT04991545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of Infrared (Active IRD/ IRRIS) device
Description: The first operator experienced with video-laryngoscopy intubation will do Before inducing anesthesia, the second operator will open the randomization envelope and adhere IRRIS/IRD device to the anterior skin of the neck above the sternal notch according to the group of patients After confirming lack of discomfort during application of the IRRIS/IRD device,~After complete relaxation, Laryngoscopy will be performed by the first operator using video laryngoscope (Glidescope Verathon Medical, BC, Canada or C-Mac Storz, Germany) to insert the tracheal tube. The endotracheal tube will be armed with a malleable stylet and to be molded to a curved 'hockey stick or the same curve of the laryngoscopic blade's shape. We will divide the patient according to device into two groups:~1. Group A: control group~2. Group B: Intervention group using Infrared
Study: NCT05683288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IASTM
Description: IASTM will be applied to the upper trapezius and sternocleidomastoid muscles of the participants for 90 seconds, with a frequency of 60 beats per minute.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release
Description: Basic movements will be performed for 3 minutes in the rectus capitis, sternocleidomastoideus, hyoid region and upper trapezius regions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 250W infrared application
Description: For 15 minutes, 250W infrared application will be applied on the cervical region from a distance of 50 cm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TENS
Description: TENS will be applied for 20 minutes at 80Hz frequency, with a current transit time of 150ms.
Study: NCT05558748

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: USG-guided Caudal block
Description: USG-guided Caudal block after general anesthesia
Study: NCT05240573

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SKI App
Description: The intervention for the SKI App digital service will include the visualization of real-time kidney data, the kidney care recommendation, and innovative artificial intelligence-based services for kidney health prediction and suggestion.~The intervention for the CMUH Dialysis Care App digital service will include simple records of blood pressure, medication records, and routine health education information.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SKI App
Description: The intervention for the SKI App digital service will include the visualization of real-time kidney data, the kidney care recommendation, and innovative artificial intelligence-based services for kidney health prediction and suggestion.~The intervention for the CMUH Dialysis Care App digital service will include simple records of blood pressure, medication records, and routine health education information.
Study: NCT06143982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intensive Trauma Treatment
Description: BITT is an outpatient, intensive, one-week individual trauma therapy program. BITT is based on well-established protocols, consisting of two 90-minutes trauma therapy sessions a day (trauma exposure in the morning and EMDR in the afternoon), two psychomotor therapy sessions a day (1x60 minutes, 1x45 minutes), one 90-minutes psycho-education and social support skill training for parents a day, and a 90-minutes family therapy session at the end of the week (sharing the trauma narrative).
Study: NCT05683288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise
Description: Cervical strengthening and stretching exercises five days a week will given
Study: NCT05262283

Intervention type: OTHER
Intervention: No intervention
Description: No intervention was made.

Intervention type: OTHER
Intervention: No intervention
Description: No intervention was made.
Study: NCT05944627

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FURESTEM-OA Kit Inj.
Description: FURESTEM-OA Kit Inj. is a combination medical product in which FURESTEM-OA Inj. (solution 1) is the primary mode of action and CAM Inj. (solution 2) acts as an auxiliary. The product is administered after mixing solution 1 and solution 2.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo administration in Phase 2a clinical trial
Study: NCT04807257

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Auger Molecular Therapy (AMT)
Description: The AMT consists of intratumorally delivered IUdR and local irradiation via AUTRON Therapy System.
Study: NCT05884944

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: Interventional Group- OMM- Muscle energy
Description: The interventional group will received Osteopathic Manipulative Medicine, specifically Muscle energy treatment. An osteopathic manipulative treatment protocol will be applied to the lower extremity joints bilaterally. Muscle energy technique (MET) will be applied to the hip, knee, and ankle bilaterally based on the protocol from Atlas of Osteopathic Techniques. The adductor, extensor, and flexor muscles of the hip joint will be treated, the extensors and flexors of the knee joint will be treated, and the plantar and dorsiflexion muscles of the ankle will be treated. Muscle energy is a direct active treatment asking the subject to move their joint in a direction against a counterforce by the treatment provider for 3 times for 3 seconds and repeating the procedure 3 times and afterwards a passive stretch to the joint is applied by the provider.
Study: NCT05567510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986369
Description: Specified dose on specified days
Study: NCT05192434

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive Writing
Description: Expressive writing (EW) is a safe, acceptable, and effective intervention for improving psychological adjustment. Via brief directed writing sessions, EW facilitates disclosure of traumatic events. At a basic level, emotional expression and disclosure are important because they reduce the need to unconsciously direct psychological energy towards suppressing emotions from traumatic events.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Contingency management (CM) is a proven strategy to reduce drug use and HIV risk behavior. Also known as a conditional cash transfer, CM reinforces positive behavior with tangible rewards. In the context of substance use treatment, monetary incentives are typically used to reinforce drug-negative urine specimens.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Contingency Management
Description: Contingency management (CM) is a proven strategy to reduce drug use and HIV risk behavior. Also known as a conditional cash transfer, CM reinforces positive behavior with tangible rewards. In the context of substance use treatment, monetary incentives are typically used to reinforce drug-negative urine specimens.
Study: NCT05790720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Patients older than 65 years of age will receive an intravenous infusion of Propofol with prespecified plasma targets. During its administration, registration of BIS values, frontal electroencephalography, and clinical signs of consciousness will be performed.
Study: NCT05800912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Narrative photography
Description: Students were shown real-life written stories, audio, and videos using a private online platform. The training activity included four modules: i) heart transplantation waiting list; ii) life expectancy, fear of death, and organ rejection; iii) post-transplant physical and functional limitations; and iv) lack of knowledge of physical exercise patients can perform.~The students were encouraged to think about how they would feel if they had undergone heart transplantation. Afterward, they had to communicate these feelings using up to three photographs and reflective explanatory text.~Two weeks later, the students met a heart transplantation expert patient followed by an educator-guided debate. Students' images were shared and discussed. Moreover, students were encouraged to explain their feelings and their acquired skills (two hours).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional learning
Description: A participatory lecture was carried out, in which cardiac rehabilitation in heart transplantation patients was explained. Then, there was an educator-guided debate about protocols and actions (one hour).~Second, the students autonomously prepared clinical cases on physical limitations, physical exercise, risk factors, and life after transplantation (two hours).~Two weeks later, the clinical session was held among students (2 hours). They adopted the roles of physical therapists or transplant patients to work on: i) post-transplant physical and functional limitations; ii) lack of knowledge of the physical exercise the patient can perform; iii) control of cardiovascular risk factors; iv) life post-transplant.
Study: NCT05104970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SunnyD insta ampoule
Description: Cholecalciferol 200000 IU insta ampoule

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: SunnyD STAT softgel capsule
Description: Cholecalciferol 200000 IU softgel capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SunnyD insta ampoule
Description: Olive oil

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SunnyD STAT softgel capsule
Description: Olive oil
Study: NCT05891678

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: doppler study of central retinal artery
Description: pulsed wave Doppler after decreasing the sample volume to fit inside the center of CRA. We will measure the peak systolic velocity (PSV), end diastolic velocity (EDV), and the resistivity index which equal PSV-EDV/PSV, we will measure 3 times and the expected normal value is less than 0.7.
Study: NCT05443815

Intervention type: DEVICE
Intervention: HaemoCer-PLUS
Description: HaemoCer-PLUS
Study: NCT04564677

Intervention type: DEVICE
Intervention: Ifabond (Péters surgical)
Description: Ifabond (Péters surgical) is a CE-marked synthetic surgical glue for internal and external use. The glue is non-toxic, biocompatible and biodegradable. It is commercially available and can be used for mesh fixation, as tissue adhesive, for sealing of sutured tissue and for hemostasis.
Study: NCT05910008

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: O-Arm Stereotactic imaging
Description: Prior to electrode implantation, O-ARm stereotactic imaging (Magnetic Resonance Imaging)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Stereotactic imaging
Description: Prior to electrode implantation, standard stereotactic imaging (Magnetic Resonance Imaging)
Study: NCT05880602

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nettle and Cranberry complex capsules
Description: A specific capsule product, containing nettle and cranberry complex will be given to participants for oral intake for 8 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo(starch)
Description: A specific capsule product, containing starch will be given to participants for oral intake for 8 weeks.
Study: NCT05686213

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: combined aerobic exercise + resistance exercise intervention (AE + RE)
Description: The AE + RE intervention group will be offered a supervised exercise program which includes both aerobic and resistance exercise. Exercise sessions will take place twice a week with a duration of 60 minutes. The training load will be tailored to a patient's individual fitness level throughout the intervention. Patient will be asked to be physically active on an additional day in the week on their own (for at least 30 minutes at moderate intensity) according to the ACSM guidelines for patients with cancer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise prior to daily radiotherapy sessions (ExPR)
Description: Patients in the ExPR in-hospital exercise intervention group will be offered an aerobic exercise program at moderate intensity. The exercise sessions will take place 5 days a week (only weekdays), and will have a duration of 30 minutes including a warming-up (5 min) and cooling-down (5 min). Total exercise volume will be aimed at 150 min per week. The sessions will take place within an hour before the daily radiotherapy session.
Study: NCT04200027

Intervention type: PROCEDURE
Intervention: total mesorectal excision
Description: Total Mesorectal Excision Total Mesorectal Excision is currently the standard technique for surgical treatment of RC. It was first described in 1982 by Bill Heald, and relies on the excision of the whole mesorectum within an intact mesorectal fascia, with the contained lymphatic system along with the tumour bearing bowel segment Total mesorectal excision
Study: NCT05558748

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: USG-guided Ilioinguinal/Iliohypogastric block
Description: USG-guided Ilioinguinal/Iliohypogastric block after general anesthesia
Study: NCT06363604

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VOMEI + PVI + linear ablation of mitral isthmus
Description: The CS angiography is firstly performed to visualize the vein of Marshall. The ethanol infusion by anhydrous alcohol is then performed by using a guidewire and an OTW ballon. For radiofrequency catheter ablation, the standard procedure of pulmonary vein isolation is performed. All the enrolled persistent AF patients perform the routine linear ablation of mitral isthmus.
Study: NCT05679271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venous stenting
Description: venous stenting associated to antiaggregation protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: observation: no treatment
Study: NCT05543083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy followed by Exercise Training
Description: 6-week group CBT (cognitive-behavioral therapy; 1 hour/week for 6 weeks) followed by 6-week group exercise training (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training followed by Cognitive-Behavioral Therapy
Description: 6-week group exercise training (1 hour/week for 6 weeks) followed by 6-week group CBT (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Therapy Only
Description: 6-week group CBT (1 hour/week for 6 weeks), with continuation of group CBT for a second 6-week period (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Training Only
Description: 6-week group exercise training (1 hour/week for 6 weeks), with continuation of group exercise for a second 6-week period (1 hour/week for 6 weeks). Home practice is assigned throughout the 12-week intervention period.
Study: NCT06363604

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VOMEI + PVI + linear ablation of mitral isthmus
Description: The CS angiography is firstly performed to visualize the vein of Marshall. The ethanol infusion by anhydrous alcohol is then performed by using a guidewire and an OTW ballon. For radiofrequency catheter ablation, the standard procedure of pulmonary vein isolation is performed. All the enrolled persistent AF patients perform the routine linear ablation of mitral isthmus.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Posterior wall isolation
Description: PWI is additionally performed for experimental group with linear ablation of LA roof and bottom line, and verified by mapping with a multielectrode catheter.